Supporting Information for

EBNA1 specific luminescencesmall molecules for imaging and inhibition of latently EBV-infected tumor cells

Lijun Jiang,^b Yin-Lai Lui,^a Hongguang Li,^b Chi-Fai Chan,^b Rongfeng Lan,^c Wai-Lun Chan,^b Terrence Chi-Kong Lau,^d George Sai-Wah Tsao,^e Nak-Ki Mak^{a*} and Ka-Leung Wong^{b*}

^aDepartment of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, Tel: 852-34117059, Email:nkmak@hkbu.edu.hk.
^bDepartment of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, Tel: 852 34112370, Email:klwong@hkbu.edu.hk.
^cHong Kong Baptist University Institute of Research and Continuing Education, Shenzhen, P. R. China;
^d Department of Biology and Chemistry, City University of Hong Kong, Kowloon Tong, Hong Kong SAR;

^e Department of Anatomy, The University of Hong Kong, Hong Kong SAR

Experimental

1) Synthesis of JLP_1 and JLP_2

All chemicals used were of reagent-grade and were purchased from Sigma-Aldrich and used without further purification. All analytical-grade solvents were dried by standard procedures, distilled and deaerated before use. NMR spectra were recorded on a Bruker Ultrashield 400 Plus NMR spectrometer. The ¹H NMR chemical shifts were referenced to tetramethylsilane, TMS (d = 0.00). High-resolution mass spectra, reported as m/z, were obtained on a Bruker Autoflex MALDI-TOF mass spectrometer. The synthetic route of intermediates and LP₁, LP₂ were shown in the figures S1.

2: Yield: 96%; ¹HNMR (CDCl₃): δ 9.24 (d, J = 6.8 Hz, 2H), 7.87 (d, J = 6.4 Hz, 2H), 4.92 (m, 2H), 2.65 (s, 3H), 1.68 (t, J = 7.2 Hz, 3H); ¹³CNMR (CDCl₃): δ 158.95, 143.67, 128.97, 56.46, 22.37, 17.14;


4: Yield: 90%; ¹HNMR (CDCl₃): δ 9.88 (s, 1H), 7.83 (d, J = 9.2 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 4.69 (s, 2H), 4.26 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H); ¹³CNMR (CDCl₃): δ 190.92, 168.24, 162.79, 132.15, 130.89, 115.06, 65.37, 61.86, 14.32;

5: Yield: 87%; ¹HNMR (MeOD): δ 8.76 (d, J = 6.8 Hz, 2H), 8.13 (d, J = 6.8 Hz, 2H), 7.90 (d, J = 16.4 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 16 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H); ¹³CNMR (MeOD): δ 178.08, 169.09, 162.74, 153.48, 150.10, 139.55, 138.09, 133.09, 130.75, 124.84, 74.33, 70.40, 64.75, 25.81, 23.68; MALDI-TOF MS: calcd. For [M⁺]: 312.16, found: 312.16;

JL: Yield: 37%; ¹HNMR (dimethyl sulfoxide – d₆): δ 8.91 (d, J = 7.2 Hz, 2H), 8.18 (d, J = 6.8 Hz, 2H), 7.98 (d, J = 16.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.38 (d, J = 16.4 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 4.77 (s, 2H), 4.50 (m, 2H), 1.52 (t, J = 7.4 Hz, 3H); ¹³CNMR (dimethyl sulfoxide – d₆): δ 169.92, 159.71, 153.15, 143.87, 140.59, 129.92, 128.25, 123.45, 121.01, 115.19, 55.14, 16.19; MALDI-TOF MS: calcd. For [M⁺]: 284.13, found: 284.17;

JLP₁: MALDI-TOF MS: calcd. For [M⁺]: 1073.46, found: 1074.92; Elemental Analysis: Calculated C = 66.78, H = 6.64, N = 10.10; Found = C = 66.18, H = 6.32, N = 10.01.

JLP₂: MALDI-TOF MS: calcd. For $[M^+]$: 970.45, found: 971.44; Calculated C = 63.72, H = 6.47, N = 10.43; Found C = 63.66, H = 6.44, N = 10.31.



a) CH₃CH₂I, ACN, 90°C, 4h;

b) BrCH₂COOCH₂CH₃, K₂CO₃, ACN, reflux, overnight;

- c) 2, Piperidine, EtOH, 90°C, 6h;
- d) 0.4 mol/L NaOH, dioxane, rt, 4h;
- e) Peptide-Resin, PyBOP, DIPEA, DMF, rt, overnight;
- f) TFA/DCM, rt, 3h.

Figure S1. The synthetic routes of JL and JLP_1/JLP_2




Figure S2. 400 MHz-1H-NMR (CDCl₃) spectrum of intermediate 2




Figure S3. 400 MHz-¹³C-NMR (CDCl₃) spectrum of intermediate 2




Figure S4. 400 MHz-1H-NMR (CDCl₃) spectrum of intermediate 4




Figure S5. 400 MHz-¹³C-NMR (CDCl₃) spectrum of intermediate 4




Figure S6. 400 MHz-1H-NMR (MeOD) spectrum of intermediate 5




Figure S7. 400 MHz-¹³C-NMR (MeOD) spectrum of intermediate 5




Figure S8. MALDI-TOF spectrum of intermediate 5

HKBU_PROTON





Figure S9. 400 MHz-1H-NMR (dimethyl sulfoxide-d₆) spectrum of JL



HKBU_CARBON

Figure S10. 400 MHz-¹³C-NMR (dimethyl sulfoxide-d₆) spectrum of JL






Figure S11. MALDI-TOF spectrum of JL








Figure S13. MALDI-TOF spectrum of JLP₂




Figure S14. The emission titration of JLP_1 upon the addition of the 200 nM EBNA1.




Figure S15. The emission spectra of JLP_2 upon the addition of the various protein and small molecules.